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tNTRODUCTION
Acute graft-versus-host disease (GVHD) is a prin-
ipal impediment to the cure of patients with blood
isorders after allogeneic stem cell transplantation.
hus, much attention has been paid to understanding
he pathophysiology of GVHD with the hope that
lucidation of the mechanisms of GVHD will improve
ur ability to both prevent and treat this complex
roblem. The working framework for allogeneic
VHD is derived from Billingham and Brent’s initial
ostulate that the development of GVHD requires
hat the graft contain immunologically competent
ells and that the host contain membrane antigens
acking in the graft, which can be recognized as for-
ign [1]. We now generally accept that donor T cells
re the immunologically competent cells and that
hese T cells recognize a set of host polypeptides as
oreign. These antigens include both major and minor
istocompatibility antigens and are thought to be
etabolic products of normal protein metabolism that
re processed through the endoplasmic reticulum and
isplayed by HLA molecules. These polypeptides are
olymorphic and lead to T-cell recognition, activa-
ion, and, ultimately, tissue injury through a variety of
ellular effector mechanisms. In essence, the donor’s
esting immune system suddenly comes in contact
ith new antigens in the setting of tissue injury that
ccompanies conditioning regimens, infection, and
he underlying disease. Direct cell-mediated attack,
roduction of inﬂammatory mediators (such as tumor
ecrosis factor alpha [TNF]– and interferon gamma
IFN]–), and recruitment of secondary effectors
uthors are listed in alphabetical order. Each author contributed equally
to this review.
B&MTompletes the accelerating cycle of cell injury and
nﬂammation that we recognize as GVHD [2]. In this
etting, the donor’s immune system now ﬁnds itself in
milieu of upregulated chemokines, cytokines, and
dhesion molecules, precisely as if there were a serious
ystemic infection [2,3]. Therefore it follows that if a
herapeutic intervention can interrupt the GVHD, it
ay also interfere with the recipient’s ability to re-
pond to infection. Thus, control of established
VHD should be associated with an increased risk of
pportunistic infections.
Corticosteroids have been the primary therapy for
cute GVHD for more than 3 decades [4]. Standard
reatment of GVHD with high-dose corticosteroids
ffects a durable response in approximately 40% of
atients after histocompatible sibling transplantation
5] and in only 24% after unrelated donor transplan-
ation [6]. Thus, 60% to 75% of patients who develop
linically signiﬁcant GVHD will require therapy be-
ond corticosteroids. For patients with steroid-refrac-
ory disease, no standard effective treatments are
vailable [7]. A variety of agents have been studied in
his setting, but outcome is generally disappointing. In
his report, we review treatment of steroid-resistant
VHD, including studies of newly available agents.
NTITHYMOCYTE GLOBULIN
The problems with the management of steroid-
efractory acute GVHD are perhaps best illustrated in
he experience with antithymocyte globulin (ATG).
TG has been a staple of GVHD therapy for many
ears and remains the most commonly used secondary
reatment, especially among pediatric transplant cen-
ers [8]. A number of studies have demonstrated that
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6TG has activity in steroid-refractory GVHD, with
9% to 56% responses overall and skin responses
rom 59% to 79% [5-16]. However, overall survival
as not improved, and 1-year mortality approaches
0%. Deaths typically are not from GVHD per se but
re primarily from opportunistic infections that follow
he prolonged and global immunosuppression. In con-
ordance with this, Arai et al. [14] demonstrated that
urvival was similarly poor for patients regardless of
heir GVHD severity at the time of starting ATG,
lthough a report from another group did show an
mprovement in survival when ATG was given as part
f early therapy [15]. The use of ATG is also compli-
ated by the fact that at least 14 different formulations
f horse- and rabbit-derived products are currently
vailable worldwide. Furthermore, different brands,
r even different lots of the same brand, of ATG may
ontain varying titers of antibodies against T-cell an-
igens, and this yields unpredictable bioactivity. The
elative efﬁcacy of horse- versus rabbit-derived ATG
as never been compared in the stem cell transplan-
ation setting. Finally, a standard dose and schedule
or ATG in the treatment of GVHD has not been
stablished, and an alarming observation was revealed
y a recent international practice survey: only 6% to
8% of the 153 responding transplant centers were
sing ATG dosing guidelines published in the litera-
ure [8].
NTI–INTERLEUKIN-2 RECEPTOR MONOCLONAL
NTIBODIES
Because activated T cells play a major role in both
he initiation and maintenance of GVHD, it was log-
cal to target cells bearing the interleukin (IL)–2 re-
eptor (IL-2R). This rationale is based on the princi-
le that T-cell activation and expansion under the
nﬂuence of IL-2 is crucial in the pathogenesis of
cute GVHD. The human IL-2R is a heteromeric
omplex composed of up to 3 polypeptide chains,
esignated as -, -, and -subunits. On the basis of
he combination of these subunits, the receptor exists
n low, medium, and high IL-2 afﬁnity binding forms.
ost resting lymphocytes and natural killer (NK) cells
xpress on their surface an intermediate-afﬁnity IL-
R, which contains the - and -chains, and expres-
ion of the -subunit (CD25) is often restricted to T
ells after antigen stimulation. The limited distribu-
ion of CD25 on activated lymphocyte subsets sug-
ests that monoclonal antibodies against this subunit
ay be used to deplete alloreactive T cells in patients
ith GVHD. In the early 1990s, murine anti–IL-2R
onoclonal antibodies were tested for steroid-refrac-
ory acute GVHD in human clinical trials. Complete
esponse (CR) rates of 66% and 73% were reported in
uman trials of the murine monoclonal antibodies
-B10 and BT563, respectively [17,18]. v
56The notion that these reagents may delete only
ctivated T cells while sparing resting T cells sug-
ested that immunologic recovery might be enhanced
ompared with a pan–T-cell antibody such as ATG.
everal monoclonal antibodies with varying human
nd mouse elements are available (Figure 1). Most
tudies in hematopoietic stem cell transplantation
ere performed with daclizumab (Zenapax; Roche
harmaceuticals, Nutley, NJ), a 144-kd humanized
mmunoglobulin G1 monoclonal antibody that binds
peciﬁcally to the -subunit (p55 , CD25, or Tac
ubunit) of the human IL-2R, where it inhibits IL-2
inding. Daclizumab has been used extensively in
olid organ transplantation, where it seems to decrease
he number and severity of rejection episodes without
ncreasing adverse events, infectious complications, or
ate malignancies [19,20]. Daclizumab demonstrated a
0% response rate in a phase I trial of steroid-refrac-
ory acute GVHD [21]. A subsequent larger trial re-
orted a CR rate of 47% when daclizumab was ad-
inistered twice weekly, whereas overall survival was
3% at 4 months [22]. Encouraging activity has also
een reported in steroid-refractory GVHD for other
ommercially available IL-2Ra antibodies, including
nolimomab (BT563) and basiliximab [18,23,24]. Lab-
ratory correlate studies revealed signiﬁcant reduc-
ions in CD3CD25 lymphocytes after daclizumab
reatment, although these reductions did not correlate
ith clinical response. On the basis of these encour-
ging results, a multicenter randomized, double-
linded, placebo-controlled trial testing the addition
f daclizumab to corticosteroids as initial therapy for
cute GVHD has recently been completed. Unfortu-
ately, there was signiﬁcantly inferior 100-day survival
77% versus 94%; P  .02) and overall survival (29%
igure 1. Available agents targeting human IL-2R: agents targeting
ctivated T cells through the IL-2 receptor. For the 3 monoclonal
ntibodies, red indicates murine structural elements, and red is the
umanized portion. For denileukin diftitox, gray represents the
L-2 molecule, and black represents the diphtheria toxin moiety.
omp/ADCC, complement activation/antibody-dependent cellular
ytotoxicity; RE-blockade, reticuloendothelial blockade. Figure is
dapted courtesy of Dr. Fred LeMaistre.ersus 60%; P  .002) when daclizumab was com-
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Steroid-Resistant Acute Graft-versus-Host Disease
Bined with corticosteroids, despite an equivalent rate
f GVHD control (53% versus 51%; P  .85) [25].
ENILEUKIN DIFTITOX
Denileukin diftitox (Ontak; Ligand Pharmaceuti-
als, San Diego, CA) is a recombinant fusion protein
ith selective cytotoxicity against activated T lympho-
ytes based on its preferential binding to high-afﬁnity
L-2R. Denileukin diftitox consists of an N-terminal
ethionine, the ﬁrst 386 amino acids of diphtheria
oxin, fused to amino acid residues 1 to 133 of IL-2.
fter internalization by IL-2R–mediated endocytosis,
he diphtheria toxin portion of the molecule is
leaved, and the catalytic A fragment is transferred to
he cytosol, where it catalyzes adenosine diphosphate
ibosylation of elongation factor 2 on ribosomes, halts
ellular protein synthesis, and triggers programmed
ell death [26].
harmcokinetics of Denileukin Diftitox
Aside from its selectivity for activated T cells,
enileukin diftitox has pharmacokinetic properties
hat may render it favorable for use in patients with
VHD. Denileukin diftitox is metabolized by ubiq-
itous proteolytic degradation, and dose adjustments
re not necessary for hepatic or renal dysfunction.
fter administration, denileukin diftitox follows dose-
roportional kinetics and exhibits monophasic clear-
nce from the serum, with a terminal half-life of 72
inutes. A phase I study in lymphoma patients has
lso established that the serum concentration of de-
ileukin diftitox does not accumulate despite repeated
aily administrations [27]. This pharmacokinetic pro-
le may have important implications in terms of min-
mizing prolonged immune suppression.
Denileukin diftitox may also be advantageous
ompared with monoclonal antibodies directed
gainst CD25 on the basis of its mechanism of action.
nlike monoclonal antibodies, which function by
locking IL-2 binding to the IL-2R and depend on
econdary effector mechanisms such as complement
ctivation or antibody-dependent cellular cytotoxicity
or cell kill, denileukin diftitox exerts its cytotoxic
ffects directly via its toxin moiety. The kinetics of this
ytotoxicity are extremely efﬁcient. In vitro studies
uggest that only 10 to 40 binding sites are necessary
n the cell surface for entry, and that entry of only 1
olecule of denileukin diftitox is sufﬁcient to induce
ell death [28].
Finally, it has been suggested that that bioactivity
f anti-CD25 monoclonal antibodies could be damp-
ned by binding to soluble IL-2R (sIL-2R), a phe-
omenon known as cold-target inhibition [29]. How-
ver, concentrations of puriﬁed sIL-2R as high as
500 pmol/L had no effect on the in vitro biologic e
B&MTctivity of denileukin diftitox. Similarly, LeMaistre
t al. [30] reported that the presence of sIL-2R did
ot prevent antitumor responses mediated by
AB486IL-2, a precursor molecule to denileukin difti-
ox. These results suggest that sIL-2R competes
oorly with denileukin diftitox for the native IL-2R
27,30].
enileukin Diftitox in Acute GVHD
Ho et al. [31] conducted a phase I study investi-
ating denileukin diftitox in 32 patients with steroid-
efractory acute GVHD. Three dose schedules were
valuated: level 1, 9 g/kg intravenously on days 1 and
5; level 2, 9 g/kg on days 1, 3, 5, 15, 17, and 19; and
evel 3, 9 g/kg on days 1 to 5 and 15 to 19. Dose
scalation was determined by dose-limiting toxicity
DLT) at each dose level. After the maximum toler-
ted dose (MTD) was determined, 10 additional pa-
ients were enrolled to assess efﬁcacy. The initial dose
f denileukin diftitox was administered over 60 min-
tes, with subsequent doses over 30 minutes. Patients
ere premedicated with diphenhydramine, acetamin-
phen, and corticosteroid. Whenever possible, the
aily steroid dose was used as premedication.
At dose level 3, all 4 evaluable patients developed
LT (1 renal failure and 3 hepatic transaminase ele-
ation). Therefore, dose level 2 was considered the
TD. Hepatic dysfunction, deﬁned as alanine ami-
otransferase or aspartate aminotransferase 5 times
aseline or the upper limit of normal or total bilirubin
3 times baseline, was the most common DLT
30%), occurring in 4 (22%) of 18 patients at the
TD. Although increased hepatic transaminase was
ommon in the week after denileukin diftitox admin-
stration, isolated hyperbilirubinemia was rare and was
bserved in only 1 patient in this trial. Other severe
dverse events potentially attributable to therapy in-
luded infusional reaction, acute renal failure, cardiac
amponade, and sepsis, but these toxicities occurred in
ery few patients and were difﬁcult to ascribe to ther-
py per se. Severe vascular leak syndrome was not
bserved, and no patient developed respiratory dis-
ress from pulmonary edema. Most patients had some
egree of peripheral edema and hypoalbuminemia be-
ore and after therapy with denileukin diftitox. Eight
f the 32 patients died during the study period. Causes
f death were GVHD, sepsis/multiorgan failure, idio-
athic pneumonia syndrome, intracranial hemor-
hage, and liver failure.
GVHD responses to denileukin diftitox are shown
n Table 1. Of the 24 patients evaluable for GVHD
esponse, 8 (33%) resolved all evidence of GVHD
CR) on or before study day 29, and 9 (38%) improved
y at least 1 grade (partial response; PR), for an overall
esponse rate of 71%. Of the PRs, 4 subsequently
ntered a CR without additional immune-suppressive
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6herapy, resulting in an overall CR rate of 50% (12/
4). GVHD response correlated with increasing dose
requency. The best responses were observed at dose
evel 2, at which 6 (46%) of 13 achieved a CR and 3
23%) had a PR that subsequently converted to a CR
fter 1 month (resulting in an overall CR rate at level
of 69%). GVHD responses to denileukin diftitox
ere substantial in patients with skin and intestine
nvolvement, with individual organ CRs of 44% and
6%, respectively, and overall response rates of 69%
o 71%. Ten patients had previously been unsuccess-
ully treated with daclizumab, and it is interesting to
ote that 8 of these patients either completely or
artially resolved the GVHD after denileukin diftitox
1 CR and 7 PRs). With extended follow-up, 9 of 30
atients treated are alive (median, 7.2 months).
mong the 12 patients who ultimately had complete
esolution of GVHD, 7 (58%) are alive. Conversely,
nly 1 of 12 evaluable patients who did not achieve a
R is alive (P  .001). There have been 5 late deaths
mong patients in CR: 3 from infection (2 bacterial
nd 1 fungal), 1 from chronic GVHD, and 1 from
elapse. No Epstein-Barr virus–associated lymphoma
r cytomegalovirus disease has been observed.
Flow cytometry of peripheral blood samples taken
uring the study period revealed low pretreatment
umbers of absolute CD3CD25 lymphocytes, and
his did not change after treatment with denileukin
iftitox. However, there was a marginally signiﬁcant
eduction in absolute NK cell and in CD3 lympho-
yte counts 1 to 7 days after treatment, followed by
risk recovery after the third week. The reduction in
bsolute CD3 count by 1 to 7 days was statistically
igniﬁcant in patients who eventually achieved a CR
P .03) but was unchanged in nonresponders. Serum
r plasma sIL-2R levels were comparable to control
ost–hematopoietic stem cell transplantation patients
ithout GVHD, and sIL-2R levels remained stable
fter denileukin diftitox. There was no correlation
able 1. GVHD Response to Denileukin Diftitox
Variable
Complete
Response
ose
Level 1 1/7 (14%)
Level 2 6/13 (46%)
Level 3* 1/4 (25%)
Overall 8/24 (33%)
rgans involved
Skin 7/16 (44%)
Intestine 9/16 (56%)
Liver 1 (25%)
VHD grade at enrollment
II 1/8 (13%)
III 5/13 (38%)
IV 2/3 (67%)
Only 1 patient at this level completed the intended 10 doses, because oetween sIL-2R level and clinical response. a
58ummary
Denileukin diftitox can be safely administered in
atients after allogeneic hematopoietic stem cell
ransplantation. A reversible increase in hepatic
ransaminases is the major DLT, but the incidence
22% at the MTD) is comparable to the 17% reported
n patients with cutaneous T-cell lymphoma [32]. De-
ileukin diftitox seems to have signiﬁcant clinical ac-
ivity in steroid-refractory acute GVHD, with com-
lete and overall response rates of 46% and 69%,
espectively, at the MTD.
Although the numbers of peripheral CD3
D25 cells were not affected by treatment, absolute
umbers of peripheral CD3 lymphocytes were tran-
iently depleted after treatment with denileukin difti-
ox, especially in patients who achieved a CR. These
esults suggest that denileukin diftitox preferentially
argets CD3 T cells that are involved in the GVHD
esponse and that resistance to therapy is associated
ith the inability of this agent to eliminate these cells
n some patients. Because treatment resulted in the
limination of CD3 T cells that did not express high
evels of CD25, these observations suggest that cells
xpressing other components of the IL-2R may also
nternalize sufﬁcient denileukin diftitox to result in
ell death in vivo. Alternatively, ﬂow cytometry may
ot be able to detect relatively low-level expression of
igh-afﬁnity receptors that may still be sufﬁcient to
ind and internalize denileukin diftitox.
Despite the encouraging GVHD responses and
mproved survival among the patients who achieved
CR, the overall survival for this entire cohort was
isappointing, and infections remained a common
ause of late mortality. Attribution of late infections
o denileukin diftitox is difﬁcult in this study be-
ause these patients had received many prior immu-
osuppressive therapies. Future clinical trials inves-
igating denileukin diftitox as primary therapy or in
Partial
Response
Overall
Response
4/7 (57%) 5/7 (71%)
3/13 (23%) 9/13 (69%)
2/4 (50%) 3/4 (75%)
9/24 (38%) 17/24 (71%)
4/16 (25%) 11/16 (69%)
3/16 (19%) 12/16 (75%)
0 1 (25%)
4/8 (50%) 5/8 (63%)
4/13 (31%) 9/13 (69%)
1/3 (33%) 3/3 (100%)
y; 4 of 9 PRs converted to CR after day 29 without additional therapy.more viable population of patients with steroid-
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Befractory disease are needed to conﬁrm the re-
ponses reported here and to determine whether
his agent improves survival for patients with acute
VHD.
YCOPHENOLATE MOFETIL
Mycophenolate mofetil ([MMF] CellCept; Roche
aboratories, Indianapolis, IN) is a morpholinoethyl
ster of mycophenolic acid (MPA). MPA possesses
ntibacterial, antifungal, antiviral, antitumor, and im-
unosuppressive properties. However, to facilitate
bsorption, it must be administered as the prodrug,
MF. Approximately 95% of the oral dose of MMF
s absorbed, and the immunosuppressive activity is
vident after de-esteriﬁcation to MPA in vivo [33].
PA mediates its immunosuppressive effect by inhib-
ting inosine monophosphate dehydrogenase, an
nzyme that catalyzes the oxidation of inosine
onophosphate to xanthine monophosphate, an in-
ermediate metabolite in the synthesis of guanosine
riphosphate. Lymphocytes rely on the de novo purine
ynthesis pathway for the nucleotides necessary for
NA synthesis, whereas other cells can also use the
alvage pathway [34-36]. Therefore, MPA depletes
he nucleotide pool, resulting in relatively selective
uppression of B- and T-cell proliferation compared
ith myeloid cells. In addition, guanosine triphos-
hate depletion may prevent recruitment of leuko-
ytes to sites of inﬂammation by inhibiting the glyco-
ylation of lymphocyte glycoproteins that are involved
n intercellular adhesion [37].
harmacokinetics of MMF
MMF is usually given orally or intravenously at
oses of 2 to 3 g/d for adults. However, therapeutic
onitoring has not been formally adopted to optimize
mmunosuppressive efﬁcacy or to minimize toxicity,
espite published reports regarding MMF’s pharma-
okinetics. MMF is rapidly and completely hydrolyzed
o MPA, which is further metabolized by glucuronyl
ransferase to form a phenolic glucuronide conjugate
MPAG), an inactive metabolite. MPAG is excreted in
he bile and urine. Although the liver is the predom-
nant organ for the metabolism of MMF, the gastro-
ntestinal tract and kidney also contribute. MMF is
ot measurable systemically in plasma after oral ad-
inistration. The mean half-life of MPA in plasma is
7.9  8.5 hours after oral administration and 16.6 
.8 hours after intravenous administration. Peak levels
f MPA occur within 1 to 2 hours of the oral dose, and
econdary peaks are usually observed at 6 to 12 hours
ecause of enterohepatic circulation. In volunteers
ith severe renal impairment, the plasma MPA area
nder the curve (AUC) was 75% higher than that
bserved in healthy volunteers. However, this is not r
B&MTredictable, and dose reduction is not necessarily rec-
mmended in the presence of renal failure. Less than
% MMF is excreted as in the urine. In a single-dose
tudy of 18 volunteers with alcoholic cirrhosis, hepatic
PA glucuronidation was relatively unaffected by he-
atic parenchymal disease. Dose adjustment has not
een recommended for patients with liver failure.
Several studies have addressed the use of thera-
eutic drug monitoring of MPA in solid organ trans-
lant recipients, although there is limited pharmaco-
inetic information in stem cell allograft recipients.
fter kidney or cardiac transplantation, there was a
igniﬁcant association between plasma concentrations
nd the development of biopsy-proven rejection [38-
0]. The importance of therapeutic drug monitoring
f MPA is stressed by the fact that in a study of 28
olid organ transplant recipients, Braun et al. [41]
ound no correlation between the MMF dose admin-
stered and MPA levels. A consensus meeting regard-
ng the monitoring of MPA has recommended a ther-
peutic window for MPA AUC of 30 to 60 g	 h/mL
nd for trough levels of 1.0 to 3.5 mg/L [42].
Very limited data are available regarding MPA
lasma concentrations and pharmacokinetics after he-
atopoietic stem cell transplantation. In studies of
MF for both prevention and treatment of acute
VHD, MPA plasma concentrations were low with
oth the oral and intravenous formulations. In one
eport in which the oral formulation of MMF was
sed for GVHD prophylaxis, the mean MMF trough
evel was only 0.28 mg/L [43]. Other studies of
VHD prophylaxis, even with the intravenous formu-
ation of MMF, have conﬁrmed the low plasma con-
entrations of MPA in the period early after transplan-
ation [44,45]. In a study of acute GVHD treatment,
PA AUC was low (at 17.8 g 	 h/mL) with stan-
ard doses of the oral formulation of MMF [46].
econdary peak plasma concentrations are much
ower after hematopoietic cell transplantation, effec-
ively shortening the half-life of the drug. The entero-
epatic circulation of MPA may be signiﬁcantly re-
uced by gut toxicity from the myeloablative
onditioning, by the presence of gastrointestinal
VHD, or by antibiotics that reduce the gut ﬂora.
hus, daily MMF doses after stem cell transplantation
ay need to be higher than the doses used for solid
rgan transplantation. It may be more effective to
ncrease the daily dose of MMF by shortening the
osing intervals rather than by increasing the dose and
aintaining the twice-daily administration. Further
tudies of MMF in the management of both acute and
hronic GVHD should consider the routine monitor-
ng of MPA plasma concentrations.
The pharmacokinetic effects of concurrent admin-
stration of calcineurin inhibitors on the disposition of
MF have been evaluated in stable renal allograftecipients [47]. When compared with a cohort of
659
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6atients receiving cyclosporine (CSP) and MMF, pa-
ients treated with tacrolimus and MMF had signiﬁ-
antly higher trough levels and AUC of MPA. These
arly results seemed to suggest that tacrolimus admin-
stration resulted in higher MPA levels when com-
ared with CSP for a given dose of MMF. More
ecent data suggested that CSP may decrease MPA
evels and that tacrolimus does not interact with MPA.
n one study, patients receiving CSP, MMF, and pred-
isone were randomized to remain on all 3 drugs,
iscontinue prednisone, or discontinue CSP [48]. The
PA levels remained unchanged in the ﬁrst 2 groups
ut increased signiﬁcantly upon discontinuation of
SP in the third group. In another study, the trough
evels of MPA in the tacrolimus group were similar to
hose of patients treated with MMF only. These re-
ults have been corroborated in a rat kidney transplant
odel [49]. It was hypothesized that coadministration
f CSP with MMF may decrease trough MPA levels
y inhibiting the secretion of MPAG into the biliary
nd gastrointestinal tract, which decreases the avail-
bility of MPA for reabsorption. This signiﬁcantly
educes the secondary plasma peak and the total AUC
f MPA. MMF doses may need to be adjusted if
atients have their calcineurin inhibitor changed,
hough clinical data supporting the beneﬁts of this
osing strategy have not been reported.
MF in Acute GVHD
MMF is a useful adjunct to calcineurin inhibitors
n preventing and treating organ graft rejection [50].
xperience with MMF after hematopoietic stem cell
ransplantation is more limited. Preclinical studies in a
urine GVHD model did not conﬁrm the effective-
ess of MMF in the control of GVHD [51]. Studies in
canine model showed that MMF alone was not very
ffective in preventing GVHD, but in combination
ith CSP it was comparable to or better than meth-
trexate and CSP [52]. In a preclinical model of non-
yeloablative transplantation, MMF and CSP after
ransplantation enhanced engraftment. Phase II clin-
cal studies have been conducted on the combination
f MMF with a calcineurin inhibitor for GVHD pre-
ention and treatment [43,44,46,53-55]. Four groups
ave reported their experience with the treatment of
cute GVHD after hematopoietic cell transplantation
able 2. Treatment of Acute GVHD with MMF: Phase II Studies
Study
No.
Patients MMF (g/d)
asara [53,54] 36 2
ash [46] 19 2–3
bhyankar [56] 7 2
audard [55] 6 2Table 2). o
60Basara et al. [54] reported their experience with
rimary treatment of grade I to IV acute GVHD in 36
atients after hematopoietic cell transplantation with
yeloablative conditioning. GVHD prophylaxis con-
isted of CSP, methotrexate, and prednisolone. MMF
as started at a dose of 250 mg orally 4 times daily,
nd after a week the dose was increased to 2 g daily.
reatment with MMF for acute GVHD was initiated
etween days 15 and 82. Of the 36 patients with acute
VHD, 26 (72%) had an overall grade improvement.
he best response was observed in the skin. Only 4 of
patients with gastrointestinal GVHD responded.
his study was difﬁcult to evaluate because the criteria
or assessing the response of acute GVHD were not
ell deﬁned. A total of 48 patients in this study with
ither acute or chronic GVHD were evaluated for
rug-related adverse events. Leukopenia was noted in
patients, but it did not necessitate discontinuation of
MF. Adverse gastrointestinal events occurred in 6 of
8 patients. The estimated 5-year survival was 37%.
Nash et al. [46] reported their experience with
MF as a treatment for steroid-refractory grade II to
V acute GVHD. Nineteen patients who had all re-
eived myeloablative conditioning were enrolled in
he study. In 18 of the 19 patients, the GVHD pro-
hylaxis was CSP and methotrexate. All patients re-
eived the oral formulation of MMF at 1 g twice daily.
response was observed in 8 (42%) patients (6 CR
nd 2 PR). MMF was discontinued in 3 patients be-
ause of neutropenia and in 1 patient because of per-
istent nausea. It was stopped in 2 other patients for
VHD progression. In pharmacokinetic studies, the
PA AUC was less in patients with acute GVHD
han in a cohort of patients from the same center with
hronic GVHD. Overall survival at 2 years was 16%.
n 2 other small reports, responses to therapy were
bserved in 6 (46%) of 13 patients [55,56].
ummary
MMF is an interesting agent for use in GVHD
rophylaxis and therapy. It has the advantage of a
ood therapeutic index, and it is a relatively selective
nhibitor of T-cell metabolism. Although the litera-
ure is sparse, MMF seems to have signiﬁcant activity
n phase II studies of primary and secondary therapy
Primary/Secondary Response
Primary 26/36 (72%); controls 5/14 (36%)
Secondary 8/19 (42%)
Secondary 2/7 (29%)
Secondary 4/6 (67%)f acute GVHD. Treatment of acute GVHD with-
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Steroid-Resistant Acute Graft-versus-Host Disease
BMF may achieve better control of GVHD with less
se of corticosteroids. Adverse effects have primarily
nvolved the gastrointestinal tract and hematopoietic
ystem but have usually not been severe and are re-
ersible with discontinuation of the drug. Plasma con-
entrations are low in general after hematopoietic cell
ransplantation compared with solid organ transplan-
ation. This suggests that improved control of GVHD
ay be achieved by optimizing the dose on the basis of
herapeutic drug monitoring.
ENTOSTATIN
Pentostatin (Nipent; Supergen, San Ramon, CA)
s a nucleoside analog that is a potent, irreversible
nhibitor of adenosine deaminase [57]. This mecha-
ism of action results in molecular and cellular effects
imilar to congenital deﬁciency of adenosine deami-
ase [58], a form of severe combined immune deﬁ-
iency with marked T lymphopenia [59]. Inhibition of
denosine deaminase blocks the metabolism of 2=-
eoxyadenosine, and in lymphocytes, the high ratio of
eoxycytidine kinase to 5-nucleotidase favors the for-
ation of 2=-deoxyadenosine 5=-triphosphate from 2=-
eoxyadenosine [57]. The accumulation of 2=-deoxy-
denosine 5=-triphosphate in lymphocytes slows cell
rowth and causes apoptosis, thereby reducing the
umber of T cells and NK cells [60-62]. By inhibiting
oth the production of IL-2 by T cells and their
esponse to IL-2 [63], pentostatin diminishes T-cell
unction [58] and inhibits antibody-dependent cellular
ytotoxicity and NK cytolytic activity [64]. Moreover,
entostatin reduces the production of TNF- [65,66]
y lipopolysaccharide-treated monocytes, an impor-
ant component in pathophysiologic models of acute
nd chronic GVHD [67,68]. In comparison with the
ther available purine nucleoside analogs, pentostatin
as relatively mild myeloid toxicity [69]; however, the
ersistence of lymphopenia for months after treat-
ent [60,61] may be advantageous in preventing re-
urrent ﬂares of GVHD and perhaps in preventing
ubsequent chronic GVHD.
Preclinical data indicate that purine nucleoside
nalogs may have a potent effect on GVHD. Both
entostatin and ﬂudarabine have prevented GVHD
nd improved survival in mouse models of allogeneic
one marrow transplantation [70,71].
harmacokinetics of Pentostatin
Pharmacokinetic analysis was performed after
ach dose for the ﬁrst 13 patients. The observed data
t a model of biexponential decay well, in accordance
ith previous pharmacokinetic studies [72-74]. Al- G
B&MThough there was considerable interpatient variation,
uch that the pentostatin exposure ranges overlapped
etween dose levels, there was a strong association
etween the assigned dose level and AUC (r2  0.51;
 .05). Two patients had pharmacokinetic monitor-
ng after dose adjustments for renal insufﬁciency ac-
ording to protocol, and the exposure levels they
chieved indicated that these dose adjustments were
ppropriate. In addition, 1 patient with liver failure
ad pharmacokinetic monitoring that demonstrated
n unexpectedly large exposure to pentostatin. This
xposure may have resulted from the distribution of
entostatin into third-space ﬂuid, which would then
ct as a reservoir for prolonged exposure. A pharma-
odynamic effect was observed on lymphocyte counts.
lthough lymphopenia was universally observed,
igher pentostatin AUC was associated with lower
ymphocyte counts 7 days after starting treatment with
entostatin (r2  0.33; P  .14). The sample size was
nsufﬁcient to assess a relationship between pentosta-
in exposure and either clinical responses or toxicities,
ut responses have occurred at exposures that ranged
rom AUCs of 1000 to 2600 ng 	 h/mL.
entostatin in Acute GVHD
Vogelsang et al. conducted a phase I dose-escala-
ion study to ﬁnd the MTD of pentostatin with clin-
cal activity in patients with steroid-refractory acute
VHD [75]. A total of 24 patients were enrolled, and
3 were evaluable. Their ages ranged from 6 months
o 63 years (median, 43 years). All had biopsy-proven
rade II to IV acute GVHD that was refractory to
ethylprednisolone (MP) at a dose of at least 2 mg/
g/d. Myeloid engraftment with an absolute neutro-
hil count of 
1000/L was required for entry onto
he study. Patients were to be assigned in cohorts of 5
o dose levels of 1, 2, 3, or 4 mg/m2/d intravenously
or 3 days. Toxicities were scored according to the
ational Cancer Institute common toxicity criteria
ersion 2.0, as modiﬁed for hematopoietic stem cell
ransplantation studies, and grade 3 or 4 toxicities
ere considered dose limiting if they were attributable
o pentostatin. The dose of pentostatin was modiﬁed
or renal insufﬁciency on the basis of the observed or
stimated creatinine clearance, as follows: for creati-
ine clearance 30 to 50 mL/min/1.73 m2, 50% of the
ose was given; at30 mL/min/1.73 m2, the dose was
eld constant. Steroids were tapered by 0.5 mg/m2/d
very fourth day either until the patient reached phys-
ologic replacement doses or, for patients whose
VHD prophylaxis included steroids, until the pa-
ient reached the planned prophylactic dose. All pa-
ients had experienced failure of primary therapy of
VHD with steroids. Nine patients had experienced
ailure of at least 1 additional line of therapy for acute
VHD.
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6A single course of 3 days of pentostatin was spec-
ﬁed by the protocol, but patients who responded to
entostatin and subsequently experienced disease
ares were treated again at the same dose level. Pen-
ostatin was generally well tolerated. Lymphopenia
as universally observed and was a desired effect of
reatment. One patient each developed grade 3
hrombocytopenia (at 1 mg/m2/d), grade 1 neutrope-
ia (at 1.5 mg/m2/d), and grade 1 transaminase in-
reases (at 1.5 mg/m2/d). The DLT was believed to be
ate infections at a dose of 2 mg/m2/d for 3 days. A
ajor challenge of this study was the attribution of
nfectious complications, because this patient popula-
ion has an intrinsic susceptibility to infection. Nev-
rtheless, the pattern of infections, including fatal
nfections with adenovirus, human herpesvirus 6
neumonia, cytomegalovirus, and sepsis, seemed to be
ttributable to the cellular immune deﬁciency associ-
ted with pentostatin. The dosage of pentostatin was
herefore de-escalated. After accrual of an additional 5
atients at 1 mg/m2/d, an intermediate dose level of
.5 mg/m2/d was established and selected as the MTD
Table 3).
Responses were evaluated at least weekly until day
8 on study. One patient died of preexisting liver
ailure on day 5 on study; this was deemed unrelated to
he study drug. The remaining 22 patients were evalu-
ble for response. Fourteen patients achieved a CR
64%), 3 had a PR (7%), 2 had a mixed response, 3
aintained stable disease, and 1 developed progressive
isease. By organ system, the response rate for skin
nvolvement was 13 CR (81%), 1 PR (6%), and 2 no
esponse; for gut, it was 11 CR (79%), 2 PR (14%),
nd 1 no response; and for liver, it was 6 CR (55%), 1
R (9%), and 4 no response. Six of the patients who
nitially responded had disease ﬂares with acute
VHD and were re-treated. All of these patients
esponded to treatment at the same dose of pento-
tatin.
The median survival remained poor—91 days
range, 5-1239 days) from study entry. However, an
ncouraging ﬁnding was that long-term survival
eached a plateau at 26%, at a median follow-up of
able 3. Clinical Outcomes of Patients with Steroid-Refractory Acute G
Dose Level*
Response
CR PR
1 5 (50%) 1 (10%)
1.5 4 (80%)
2 5 (83%) 1 (17%)
3 0 1 (100%)
eaths were attributed to refractory acute GVHD, refractory chro
R indicates mixed response; NR, no response.
Dose in mg/m2/d, intravenously, for 3 days.40 days (range, 180-1059 days). The major cause of d
62eath was infection. Four patients died of refractory
cute GVHD, 1 of refractory chronic GVHD, and 2
f bronchiolitis obliterans. Only 2 patients had re-
apses of the underlying disease. These patients were
reated with donor lymphocyte infusions and suc-
umbed to infections afterward.
ummary
Pentostatin has encouraging activity in steroid-
efractory acute GVHD, and most patients achieved a
R and had no evidence of active GVHD within 4
eeks of treatment with a single 3-day course of pen-
ostatin. However, a substantial minority of patients
xperienced disease ﬂares with acute GVHD and re-
uired a second course of therapy. Mortality remained
igh, primarily because of infections, despite aggres-
ive protocol-mandated tapering of steroids in the
atients with steroid-refractory disease. Pentostatin
xposure, as measured by AUC, was signiﬁcantly as-
ociated with the assigned dose level, and although the
ose adjustment for renal insufﬁciency was appropri-
te, it is also important to consider dose reduction in
he setting of hepatic failure, presumably due to the
resence of third-space ﬂuid. The recommended dose
or phase II investigation is 1.5 mg/m2/d intravenously
or 3 days, with a second course to be administered in
weeks, except in patients who have signiﬁcant infec-
ions or who remain severely lymphopenic. Additional
harmacokinetic data would be of great value in a
hase II trials to clarify the relationship between ex-
osure and clinical outcomes. It is possible that expo-
ure-based or glomerular ﬁltration rate–based dosing
ould produce more consistent outcomes than dosing
n the basis of body-surface area. Ultimately, using
his therapy earlier in the course of GVHD is likely to
e necessary to avoid the mortality associated with
teroid-refractory GVHD.
NFLIXIMAB
The rationale for the use of inﬂiximab in the
herapy of GVHD differs from that for the agents
Treated at Various Dose Levels of Pentostatin
Survival
GVHD-
Specific
MortalityNR
%) 2 (20%) 2 (20%) 3 (30%)
1 (20%) 2 (40%) 3 (60%)
2 (33%) 1 (17%)
0 (0%) 0 (0%)
HD, or bronchiolitis obliterans.VHD
MR
2 (20
nic GVescribed previously. Because inﬂammatory cytokines
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Steroid-Resistant Acute Graft-versus-Host Disease
Bre important mediators of acute GVHD [2], several
nvestigators have studied known and putative inhib-
tors of TNF- and of IL-1. Both the IL-1 receptor
ntagonist anakinra (Kineret; Amgen, Thousand
aks, CA) and the sIL-1 receptor had demonstrable
ctivity (50%-60% response rate) in steroid-refractory
VHD [76,77]. Subsequent studies showing that the
L-1 receptor antagonist was ineffective as GVHD
rophylaxis dampened enthusiasm for further trials in
cute GVHD. However, this drug may deserve a sec-
nd look as therapy alone or in combination with
ther cytokine inhibitors.
High levels of TNF- have been observed in
VHD in bone marrow transplant recipients [78,79].
NF- is mainly produced by monocytes and macro-
hages and secondarily by T lymphocytes and NK
ells [80-82]. The cellular effects of TNF- are me-
iated through the induction of apoptosis in target
issues, but the cytokine also has profound effects on
he immune response by inducing nuclear factor-B,
itric oxide synthetase, adhesion molecules (eg, inter-
ellular adhesion molecule-1), IL-2R, major histo-
ompatibility complex class I and II, and secreted
roteins such as IL-1, IL-6, IL-8, IL-12, IFN-, gran-
locyte-macrophage colony-stimulating factor, plate-
et-derived growth factor, and urokinase-type plas-
inogen activator. In addition, there is activation of
acrophages, dendritic cells, neutrophils, eosinophils,
cells, and T cells and facilitation of T-lymphocyte
ysis [2,83].
Multiple inhibitors of TNF- activity have been
escribed, including steroids [84], pentoxifylline [85],
ransforming growth factor- [86], and IL-4 [87].
linical trials of murine monoclonal antibodies to
NF- have shown transient improvement in acute
VHD [83,88,89]; however, limitations in the use of
urine monoclonal antibodies have prevented large-
cale deﬁnitive trials. A humanized monoclonal anti-
ody to TNF-, such as inﬂiximab, might beneﬁt
rom better pharmacodynamics.
Inﬂiximab (Remicade; Centocor, Malvern, PA) is
n immunoglobulin G1 murine/human chimeric
onoclonal antibody composed of human constant
nd murine variable regions that binds both the solu-
le subunit and the membrane-bound precursor of
NF- [90]. Inﬂiximab inhibits a broad range of bi-
logical activities of TNF- by blocking its interac-
ion with its receptors, and it may also cause lysis of
ells that produce TNF- [90]. The drug has been
sed with success for the treatment of a range of
utoimmune and inﬂammatory diseases, including
rohn disease, rheumatoid arthritis, psoriasis, and
pondyloarthropathies [91-97]. The median terminal
alf-life of inﬂiximab ranges from 8 to 10 days, and it
s distributed primarily within the vascular compart-
ent. b
B&MTnfliximab in Acute GVHD
Three studies involving a total of 14 patients with
cute GVHD treated with inﬂiximab have been re-
orted [88,98,99]. All patients had advanced steroid-
esistant acute GVHD and received inﬂiximab at 10
g/kg/wk for a median of 4 doses. Signiﬁcant re-
ponses were seen in several patients with severe gas-
rointestinal disease, and the drug was not apparently
ssociated with any major immediate toxicity.
Couriel et al. [83] conducted a retrospective anal-
sis of 21 patients with steroid-resistant acute GVHD
ho received inﬂiximab added as a single agent to
acrolimus and corticosteroids for the initial treatment
f steroid-resistant acute GVHD. Patients who devel-
ped acute GVHD continued on tacrolimus, main-
aining blood levels between 5 and 15 ng/mL, and
eceived MP 2 mg/kg/d in divided doses. Patients
hose GVHD was steroid resistant received inﬂix-
mab at 10 mg/kg once weekly for 4 doses (median, 4;
ange, 2-9); additional doses were allowed for PRs.
acrolimus was maintained throughout therapy, and
P was tapered from the initial dose of 2 mg/kg/d as
olerated when signiﬁcant improvement was achieved
at least a PR). Responses were assessed for each in-
olved organ. CRs and PRs were assessed 7 days after
he initiation of inﬂiximab. Patients were considered
onresponders if the GVHD had not improved or
rogressed 7 days after the initiation of inﬂiximab for
kin GVHD or 72 hours after its initiation for visceral
VHD. Responses were observed in 14 patients
67%), and 13 of these patients (62%) had a CR. Five
atients (24%) did not respond, and 2 (10%) had
rogression of their GVHD.
The best responses were seen in patients with
ntestinal GVHD, with 8 CRs and 1 PR among 12
atients. Of 10 patients with cutaneous acute GVHD,
had a CR, and 1 had a PR. Of 4 patients with liver
nvolvement, 1 had CR, and 3 did not respond. Age,
ex, HLA compatibility (related versus unrelated
ransplant), and overall grade (grade II versus III/IV)
ere evaluated as prognostic factors for response to
nﬂiximab. None of these factors reached statistical
igniﬁcance. Among patients who responded to inﬂix-
mab with a CR or a PR, chronic GVHD developed in
3%. There were no infusion, allergic, or other toxic
eactions to inﬂiximab.
The duration of response was measured from the
ime of ﬁrst inﬂiximab treatment to the day of disease
rogression or initiation of additional immunother-
py. Response duration exceeded 14 days in all 14
atients with a CR or a PR and exceeded 30 days in 11
atients. Ten of the patients who had a CR after
nﬂiximab did not require any further immunosup-
ressive therapy. The remaining 3 patients subse-
uently required salvage immunosuppression after
rief remissions.
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6Infections are summarized in Table 4. These data
mphasize that although the salvage therapy with in-
iximab seemed effective, the risk of infection was
ubstantial. Another retrospective analysis of invasive
ungal infection in patients receiving salvage therapy
or steroid-resistant GVHD observed a hazard ratio
or inﬂiximab exposure of 13.6 (P .004) [100]. Eight
atients remained alive at a median follow-up of 21
onths (range, 11-31 months). Thirteen patients
62%) died, and all of the 8 surviving patients have
hronic GVHD. The Kaplan-Meier estimate of over-
ll survival for all patients from the time of transplan-
ation was 38%. The median survival since transplan-
ation was 8.7 months (95% conﬁdence interval, 0.30
o 0.71). Acute (n  1) and chronic (n  8) GVHD
able 6. Summary of Activity of Available Agents in Steroid-Resistant
Agent Mechanism Tox
ntithymocyte
globulin
Complement
fixation, ADCC
Infection,
lympho
disorde
aclizumab Complement
fixation, ADCC
of
IL-2R–expressing
cells
Infection,
lympho
disorde
enileukin
diftitox
Intoxication of
cells expressing
IL-2 receptor
Infection,
transam
ycophenolate
mofetil
Inhibition of
IMPDH;
relatively
selective for T
cells
Infection,
diarrhe
entostatin Inhibition of ADA Infection,
myelos
nfliximab Binding of TNF- Infection
DCC indicates antibody-dependent cellular cytotoxicity; IMPD
able 4. Infections after Inﬂiximab Therapy
Type of Infection
Patients,
n (%)
Positive
Cultures, n (%)
acterial 17 (81) 40 (49)
Gram-positive 11 32
Gram-negative 5 8
Others 4 5
ungal 10 (48) 18 (22)
Aspergillus sp 6 7
Candida glabrata 5 5
Candida sp 4 6
iral 14 (67) 24 (29)
Cytomegalovirus 11 16
Respiratory
viruses 5 5
Others 3 3
otal 21 (100) 82 (100)EBV, Epstein-Barr virus.
64ere the main causes of death (69%), followed by
ecurrence of malignancy (n  3; 23%) [101].
The encouraging response rate in such a poor-risk
atient population led to a phase III study of up-front
reatment of acute GVHD in hopes of better response
nd survival with treating GVHD at an earlier stage.
ifty-eight patients with untreated acute GVHD were
andomized to receive MP (n  28) or MP plus
nﬂiximab (n  30) in an open-label trial. Sex, age,
rgan involvement, and severity of GVHD were sim-
lar in both arms (data not shown). Inﬂiximab was well
olerated, and no acute or infusion-related reactions
ere noted in the steroid-refractory or phase III ex-
erience. Overall response (CR/PR) rates were similar
n both the MP (63%; n 15) and the MP plus
nﬂiximab (66%; n 20) groups, with no differences
n response by organ. The death rate was similar in
able 5. Causes of Death after Primary Therapy for Acute GVHD
ith Corticosteroid with or without Inﬂiximab
Variable Methylprednisolone
Methylprednisolone
 Infliximab
28 30
omplete
remission 18 (64%) 19 (63%)
ause of death
GVHD 8 8
Relapse 8 5
Infection 1 1
Multiorgan
failure 0 3
Other 1 2
VHD
Efficacy
n CR PR Overall
rative
— — — 19%-56%
rative
43 37% 14% 51%
a, 24 50% 21% 71%
a, 68 59%
sion
22 64% 14% 73%
21 62% 5% 67%
ine monophosphate dehydrogenase; ADA, adenosine deaminase;Acute G
icity
EBV
prolife
r
EBV
prolife
r
edem
initis
nause
a
uppres
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Steroid-Resistant Acute Graft-versus-Host Disease
Both study arms as well, and the main cause was
VHD followed by relapse of the underlying malig-
ancy (Table 5).
ummary
Despite initial encouraging results, preliminary
esults showed no signiﬁcant differences in response
etween the MP and MP plus inﬂiximab groups. In
he M.D. Anderson phase III experience, the inci-
ence of infection and causative organisms were sim-
lar in both groups, although an increased risk of
ungal infections has been recently reported, and cau-
ious use of this agent should probably include anti-
ungal prophylaxis [100]. Despite encouraging re-
ponse rates in the steroid-refractory setting,
reatment of acute GVHD at an earlier stage with
nﬂiximab did not prove more effective than steroids
lone. Once established, GVHD continues to be the
ain cause of death.
ONCLUSION
A summary of the activity for available agents in
teroid-resistant acute GVHD is presented in Table 6.
number of other immunosuppressive agents are
emonstrably active as second-line therapy, but each
ay further predispose patients to life-threatening
nfections. For instance, neither CD5 immunotoxins
4,102], nor monoclonal antibodies directed against T
ells [17,18,21-23,103-107], nor monoclonal antibod-
es directed against TNF [83,88,89], nor extracorpo-
eal phototherapy [108,109], nor very-high-dose cor-
icosteroids [110,111] have been demonstrably helpful
n improving survival [5,7]. Many patients die of in-
ections whether or not the GVHD has entered re-
ission [100]. Because high-dose corticosteroids are a
igniﬁcant risk factor for infections, diabetes, bone
oss, and nutritional compromise, intensiﬁcation of
mmunosuppression with nonsteroidal agents to con-
rol GVHD along with an accelerated taper of steroids
ay reduce the risk for infections and overall morbid-
ty. Supportive care of patients with GVHD may in-
olve attention to nutritional support, bone mineral
etention and repair, and intensiﬁed infection prophy-
axis. Because the current prognosis for patients with
teroid-resistant GVHD is poor and because the
raft-versus-tumor reaction is critical for the thera-
eutic effect of transplantation, emphasis in clinical
tudies needs to be on initial control of acute GVHD,
hus sparing larger patient groups the extended mor-
idity and mortality that accompany the often ineffec-
ive treatment of advanced and steroid-refractory
VHD.
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